Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | PDK1 | Q15118 | 5/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.44 |
| ▸ | DHODH | Q02127 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2909726 | 0.90 | GRM2 (0.46) | RECQLCYP1A2CYP3A4TSHRBLM | |
| SCHEMBL2905903 | 0.90 | MKNK1 (0.52) | RECQLPDK1L3MBTL1ALDH1A1USP2 | |
| SCHEMBL4190655 | 0.88 | ALDH1A1 (0.50) | CYP1A2CYP3A4TSHRBLML3MBTL1 | |
| SCHEMBL2910411 | 0.85 | GRM2 (0.46) | L3MBTL1ALDH1A1USP2NPSR1GRM2 | |
| SCHEMBL4198518 | 0.84 | GRM2 (0.47) | CYP1A2CYP3A4TSHRBLMPDK1 | |
| SCHEMBL1157710 | 0.84 | MAPT (0.47) | CYP1A2CYP3A4TSHRBLML3MBTL1 | |
| SCHEMBL4186765 | 0.84 | GRM2 (0.47) | TSHRL3MBTL1ALDH1A1USP2NPSR1 | |
| SCHEMBL3129016 | 0.84 | TSHR (0.50) | TSHRL3MBTL1ALDH1A1USP2NPSR1 | |
| SCHEMBL2907011 | 0.83 | GRM2 (0.46) | CYP1A2CYP3A4TSHRBLMPDK1 | |
| SCHEMBL2909823 | 0.83 | MEP1B (0.49) | CYP1A2CYP3A4TSHRBLML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2007513957-A | — | — | 2007-05-31 | — | — | JP | claimed |
| EP-1692109-A2 | PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED DIARYLAMINE ANALOGS | Memory Pharmaceuticals Corporation (US) | 2006-08-23 | — | — | EP | claimed |
| US-20050222207-A1 | Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs | MEMORY PHARMACEUTICAL CORPORATION | 2005-10-06 | — | — | US | claimed |
| WO-2005061458-A2 | PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED DIARYLAMINE ANALOGS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2005-07-07 | — | — | WO | claimed |
| EP-1692109-B1 | PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED DIARYLAMINE ANALOGS | MEMORY PHARM CORP (US) | 2010-08-18 | — | — | EP | disclosed |
| EP-1692109-A2 | PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED DIARYLAMINE ANALOGS | Memory Pharmaceuticals Corporation (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20050222207-A1 | Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs | MEMORY PHARMACEUTICAL CORPORATION | 2005-10-06 | — | — | US | disclosed |
| WO-2005061458-A2 | PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED DIARYLAMINE ANALOGS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2005-07-07 | — | — | WO | disclosed |
| WO-2005061458-A2 | PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED DIARYLAMINE ANALOGS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222207-A1 | Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs | PDE4A, PDE4B, PDE3B | RECQL 137/4885CYP1A2 256/4885CYP3A4 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.